New combo shows promise for tough liver cancers
NCT ID NCT06631326
First seen Jan 31, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study looked at 244 people with advanced liver cancer that had spread into a major blood vessel. Researchers compared standard treatment (lenvatinib plus an immunotherapy drug) to the same treatment plus a direct liver chemo infusion. The goal was to see if the triple combination helped people live longer and kept tumors from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The first hospital of China medical university
Shenyang, Liaoning, 110000, China
Conditions
Explore the condition pages connected to this study.